Disease · HP_0000132

Menorrhagia

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Menorrhagia. Diseases, record HP_0000132. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0000132

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Menorrhagia; Open Targets
Open Targets ID: HP_0000132; Open Targets
Other names: Abnormally heavy bleeding during menstruation, Abnormally heavy periods, Hypermenorrhea; Open Targets
NCI Thesaurus: C26829; NCI Thesaurus
Highest stage of its drugs: Approval, for 8 of its 23 drugs, from DailyMed, PMDA and TTD; Open Targets

Drugs23

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
LEVONORGESTREL	CHEMBL1389	Small molecule	Approval	DailyMed	13	11	9	Drugs and targets
TRANEXAMIC ACID	CHEMBL877	Small molecule	Approval	DailyMed	18	10	10	Drugs and targets
DIENOGEST	CHEMBL1201864	Small molecule	Approval	DailyMed	3	2	2	Drugs and targets
DANAZOL	CHEMBL1479	Small molecule	Approval	TTD	1	0	0	Drugs and targets
ESTRADIOL VALERATE	CHEMBL1511	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
ETHAMSYLATE	CHEMBL1514715	Small molecule	Approval	TTD	1	0	0	Drugs and targets
NORGESTREL	CHEMBL2107797	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
RELUGOLIX	CHEMBL1800159	Small molecule	Approval	PMDA	1	0	0	Drugs and targets
LINZAGOLIX	CHEMBL3668014	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
LEUPROLIDE ACETATE	CHEMBL1200775	Protein	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 23

See all 23 drugs

Targets14

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PGR	Progesterone receptor	8	Progesterone receptor agonist; Progesterone receptor antagonist; Progesterone receptor modulator	Approval	https://conductscience.org/library/genes/5241	Drugs and targets
GNRHR	Gonadotropin-releasing hormone receptor	3	Gonadotropin-releasing hormone receptor agonist; Gonadotropin-releasing hormone receptor antagonist	Approval	https://conductscience.org/library/genes/2798	Drugs and targets
ESR1	Estrogen receptor	2	Estrogen receptor alpha agonist	Approval	https://conductscience.org/library/genes/2099	Drugs and targets
AR	Androgen receptor	1	Androgen Receptor agonist	Approval	https://conductscience.org/library/genes/367	Drugs and targets
AVPR1A	Vasopressin receptor	1	Vasopressin receptor agonist	Unknown	https://conductscience.org/library/genes/552	Drugs and targets
AVPR1B	Vasopressin receptor	1	Vasopressin receptor agonist	Unknown	https://conductscience.org/library/genes/553	Drugs and targets
AVPR2	Vasopressin receptor	1	Vasopressin receptor agonist	Unknown	https://conductscience.org/library/genes/554	Drugs and targets
IL11RA	Interleukin-11 receptor subunit alpha	1	Interleukin 11 receptor alpha agonist	Phase 2	https://conductscience.org/library/genes/3590	Drugs and targets
NR3C1	Glucocorticoid receptor	1	Glucocorticoid receptor antagonist	Phase 2/3	https://conductscience.org/library/genes/2908	Drugs and targets
NR3C2	Mineralocorticoid receptor	1	Mineralocorticoid receptor antagonist	Phase 1/2	https://conductscience.org/library/genes/4306	Drugs and targets

1 to 10 of 14

See all 14 targets

Trials28

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00113568	Safety Study of XP12B in Women With Menorrhagia	Phase 3	784	2010-01-20	Menorrhagia, Heavy Menstrual Bleeding	TRANEXAMIC ACID	Its record names the disease	ClinicalTrials.gov
NCT00401193	Efficacy and Safety of XP12B in Women With Menorrhagia	Phase 3	304	2010-02-24	Menorrhagia, Heavy Menstrual Bleeding	TRANEXAMIC ACID	Its record names the disease	ClinicalTrials.gov
NCT01280981	A Study of Tranexamic Acid (XP12B) in Women With Heavy Menstrual Bleeding	Phase 3	288	2011-07-26	Menorrhagia	TRANEXAMIC ACID	Its record names the disease	ClinicalTrials.gov
NCT00966264	Hysterectomy and Levonorgestrel Releasing Intrauterine System (LNG-IUS) in the Treatment of Menorrhagia	Phase 3	236	2009-08-26	Menorrhagia	LEVONORGESTREL	Its record names the disease	ClinicalTrials.gov
NCT00360490	Study in Women With Idiopathic Menorrhagia to Determine the Reduction in Menstrual Blood Loss (MBL) After Treatment With the Levonorgestrel-releasing Intrauterine System (IUS)	Phase 3	165	2009-11-19	Menorrhagia	LEVONORGESTREL, MEDROXYPROGESTERONE ACETATE	Its record names the disease	ClinicalTrials.gov
NCT02606045	Minimize Menorrhagia in Women With Von Willebrand Disease	Phase 3	39	2024-07-01	Von Willebrand Diseases	TRANEXAMIC ACID, VON WILLEBRAND FACTOR HUMAN	Its record names the disease	ClinicalTrials.gov
NCT01428713	Tranexamic Acid (TA) vs Combined Oral Contraceptive (COCP) Pilot Study	Not applicable	17	2014-09-17	Menorrhagia	LEVONORGESTREL, TRANEXAMIC ACID	Its record names the disease	ClinicalTrials.gov
NCT00524342	IL-11 in Women With Von Willebrand Disease and Refractory Menorrhagia	Phase 2	7	2014-11-07	Von Willebrand Disease	OPRELVEKIN	Its record names the disease	ClinicalTrials.gov
NCT00556400	Treatment of Menorrhagia in Women With Thrombocytopenia Using Platelets or Platelets and Hormones	Phase 1/2	1	2013-07-11	Aplastic Anemia, Menorrhagia, Amenorrhea	ETHINYL ESTRADIOL	Its record names the disease	ClinicalTrials.gov
NCT00883662	Mirena Observational Program		2,725		Contraception, Menorrhagia, Endometrial Hyperplasia, Estrogen Replacement Therapy	LEVONORGESTREL	Its record names the disease	ClinicalTrials.gov

1 to 10 of 28

See all 28 trials

Comparisons in its trials4

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Levonorgestrel Intrauterine System (LNG IUS) 20µg Per 24 Hours vs Medroxyprogesterone Acetate (MPA): serious adverse events	1 of 82	0 of 83	165	NCT00360490	Trial comparisons
Tranexamic Acid vs Recombinant Von Willebrand Factor: deaths from any cause	0 of 36	0 of 36	72	NCT02606045	Trial comparisons
Tranexamic Acid vs Recombinant Von Willebrand Factor: serious adverse events	0 of 36	0 of 36	72	NCT02606045	Trial comparisons
Tranexamic Acid (TA) vs Combined Oral Contraceptives (COCP): serious adverse events	0 of 10	0 of 11	21	NCT01428713	Trial comparisons

Papers from its trials23

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
35123042	RESULT	1	PubMed
34961515	RESULT	1	PubMed
33590656	RESULT	1	PubMed
32767677	RESULT	1	PubMed
29845696	RESULT	1	PubMed
22959906	RESULT	1	PubMed
21833452	RESULT	1	PubMed
21475963	RESULT	1	PubMed
20733445	RESULT	1	PubMed
20472114	RESULT	1	PubMed

1 to 10 of 23

See all 23 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/HP_0000132

GET https://conductscience.org/api/diseases/v1/HP_0000132/drugs?page=2

API reference For AI assistants